Early anti-scarring treatment for stable lung fibrosis
Part of Lungs & breathing clinical trials.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old.
- You have been diagnosed with a type of lung scarring (fibrosis) that is not actively getting worse.
- Your breathing tests show moderate lung function (not too low and not too high).
- You do not have other serious lung diseases like emphysema or asthma.
- You are not a current smoker and have quit at least 3 months ago.
- You are willing to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to find and treat fibrotic interstitial lung disease (a condition where lung tissue becomes scarred and stiff) as early as possible. It may help people with this type of lung disease get better care.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This study uses a single lung scan to find early signs of progressive scarring (fibrosis) in people with pulmonary fibrosis. It may help doctors predict which patients will get worse faster.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
Hear when a new Fibrotic Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.